A Phase 3 interventional study of Brexpiprazole and Sertraline in Post Traumatic Stress Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sertraline in Stress Disorders, Post-Traumatic — none open to participants now, none under way, none of them phase 3. Sertraline · Stress Disorders, Post-Traumatic.
Among the 22 studies testing sertraline in Stress Disorders, Post-Traumatic, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2019, is one of 4 in phase 3, and was the 21st registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →None of the 22 studies testing sertraline in Stress Disorders, Post-Traumatic is open now. The open studies under Stress Disorders, Post-Traumatic, anywhere →
Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5 · Phase 4 11
First in 2002; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 591 is above the median of 69 across 2,201 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 80 across the 21 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd.: 3 open now, 3 under way, 3 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd., this one has the largest enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 3rd registered.
Otsuka Holdings Co., Ltd.’s Stress Disorders, Post-Traumatic studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sertraline in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 11 in Stress Disorders, Post-Traumatic:
This tab as a report to print or save as PDF → With an account.
This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants received brexpiprazole-matched placebo tablets and sertraline-matched placebo tablets during the 1-week placebo run-in period.
Other: Placebo
Randomized participants received brexpiprazole 2 milligrams (mg), orally, once daily (QD) in combination with sertraline, 150 mg, orally, QD from Week 1 to Week 12 of the double-blind treatment (DBT) period.
Drug: Sertraline · Drug: Brexpiprazole
Randomized participants received brexpiprazole 3 mg, orally, QD in combination with sertraline, 150 mg, orally, QD from Week 1 to Week 12 of the DBT period.
Drug: Brexpiprazole · Drug: Sertraline
Randomized participants received sertraline 150 mg, orally, QD, in combination with sertraline matching placebo, orally, QD from Week 1 to Week 12 of the DBT period.
Drug: Sertraline · Other: Placebo
3 mg pill
Also known as: Rexulti
150 mg pill
Also known as: Zoloft
Pill
2 mg pill
Also known as: Rexulti
Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score
CAPS-5 was a structured interview designed to assess PTSD diagnostic status and symptoms severity as defined by DSM-5. CAPS -5 total score was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B: Intrusion symptoms (5 items); Category C: Avoidance symptoms (2 items); Category D: Cognition and mood symptoms (7 items); Category E: Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B, C, D, E. Each symptom was scored 0=Absent to 4=Extreme/incapacitating, to yield a score range of 0-80. Higher scores indicate worse outcome. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.
Time frame: Baseline (Week 1), Week 10
Change in Clinical Global Impression - Severity (CGI-S) Score
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (not assessed) was to be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.
Time frame: Baseline (Week 1), Week 10
Change in Brief Inventory of Psychosocial Functions (B-IPF) Score
The B-IPF is a short patient-reported questionnaire consisting of 7 questions which measure PTSD-specific psychosocial function on a 7-point Likert scale (0 = not at all to 6 = very much, and a not applicable option) with a recall period of 30 days. The B-IPF measures the concepts of romantic relationships, parenting, family, friendships and socializing, work, education, and self-care. Total score ranges from 0-100 and is calculated by summing the completed scale items, dividing by the maximum possible score of all items and multiplying by 100. Higher scores indicate greater impairment. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.
Time frame: Baseline, Week 12
A total of 591 participants took part in the study at 75 investigative sites in the United States from 30 October 2019 to 15 August 2023.
| Milestone | Placebo | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|---|
| Started | 591 | 0 | 0 | 0 |
| Completed | 553 | 0 | 0 | 0 |
| Not completed | 38 | 0 | 0 | 0 |
| Withdrew: Not randomized | 38 | 0 | 0 | 0 |
| Milestone | Placebo | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|---|
| Started | 0 | 191 | 185 | 177 |
| Randomized sample | 0 | 191 | 185 | 177 |
| Enriched randomized sample | 0 | 143 | 136 | 138 |
| Full analysis set (fas) enriched sample | 0 | 132 | 126 | 130 |
| Safety sample | 0 | 185 | 180 | 172 |
| Completed | 0 | 126 | 123 | 116 |
| Not completed | 0 | 65 | 62 | 61 |
| Withdrew: Adverse event | 0 | 9 | 9 | 8 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 22 | 11 | 25 |
| Withdrew: Non-compliance with study drug | 0 | 4 | 4 | 2 |
| Withdrew: Physician decision | 0 | 1 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 7 | 6 | 4 |
| Withdrew: Withdrawal by subject | 0 | 19 | 29 | 14 |
| Withdrew: Reason not specified | 0 | 1 | 3 | 6 |
CAPS-5 was a structured interview designed to assess PTSD diagnostic status and symptoms severity as defined by DSM-5. CAPS -5 total score was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B: Intrusion symptoms (5 items); Category C: Avoidance symptoms (2 items); Category D: Cognition and mood symptoms (7 items); Category E: Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B, C, D, E. Each symptom was scored 0=Absent to 4=Extreme/incapacitating, to yield a score range of 0-80. Higher scores indicate worse outcome. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.
| score on a scale | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|
| Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score | -16.53 ± 1.19 | -18.28 ± 1.23 | -17.57 ± 1.19 |
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (not assessed) was to be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.
| score on a scale | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|
| Change in Clinical Global Impression - Severity (CGI-S) Score | -1.26 ± 0.10 | -1.31 ± 0.11 | -1.29 ± 0.10 |
The B-IPF is a short patient-reported questionnaire consisting of 7 questions which measure PTSD-specific psychosocial function on a 7-point Likert scale (0 = not at all to 6 = very much, and a not applicable option) with a recall period of 30 days. The B-IPF measures the concepts of romantic relationships, parenting, family, friendships and socializing, work, education, and self-care. Total score ranges from 0-100 and is calculated by summing the completed scale items, dividing by the maximum possible score of all items and multiplying by 100. Higher scores indicate greater impairment. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.
| score on a scale | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|
| Change in Brief Inventory of Psychosocial Functions (B-IPF) Score | -27.12 ± 2.67 | -31.79 ± 2.86 | -22.96 ± 2.71 |
Collected over From the first dose of the study drug up to 21 days after the last dose (Up to Week 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole (2 mg) + Sertraline | 1/185 (0.5%) | 1/185 (0.5%) | 31/185 (16.8%) |
| Brexpiprazole (3 mg) + Sertraline | 0/180 (0%) | 1/180 (0.6%) | 35/180 (19.4%) |
| Sertraline + Placebo | 0/172 (0%) | 3/172 (1.7%) | 36/172 (20.9%) |
| Event | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|
| ManiaPsychiatric disorders | 0/185 | 0/180 | 1/172 |
| Suicidal IdeationPsychiatric disorders | 0/185 | 0/180 | 1/172 |
| HypertensionVascular disorders | 0/185 | 0/180 | 1/172 |
| Cyst RuptureGeneral disorders | 0/185 | 1/180 | 0/172 |
| DrowningGeneral disorders | 1/185 | 0/180 | 0/172 |
| Event | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/185 | 15/180 | 15/172 |
| HeadacheNervous system disorders | 13/185 | 10/180 | 13/172 |
| DiarrhoeaGastrointestinal disorders | 7/185 | 11/180 | 11/172 |
| InsomniaPsychiatric disorders | 7/185 | 7/180 | 9/172 |
Randomized Sample included all participants randomized into this trial.
| Age, Continuous(years) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| Mean | 37.1 ± 12.1 | 36.3 ± 11.7 | 37.7 ± 12.3 | 37.0 ± 12.1 |
| Sex: Female, Male(Participants) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| Female | 142 | 141 | 126 | 409 |
| Male | 49 | 44 | 51 | 144 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 48 | 37 | 37 | 122 |
| Not Hispanic or Latino | 143 | 146 | 140 | 429 |
| Unknown | 0 | 1 | 0 | 1 |
| Other | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| White | 130 | 124 | 121 | 375 |
| Black or African American | 46 | 45 | 44 | 135 |
| American Indian or Alaska Native | 3 | 1 | 2 | 6 |
| Asian | 6 | 8 | 5 | 19 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 3 |
| Other | 4 | 6 | 5 | 15 |
| Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score(score on a scale) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| Mean | 38.8 ± 8.3 | 37.8 ± 7.3 | 39.3 ± 7.8 | 38.7 ± 7.8 |
| Clinical Global Impression - Severity (CGI-S) Score(score on a scale) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| Mean | 4.6 ± 0.7 | 4.5 ± 0.7 | 4.7 ± 0.7 | 4.6 ± 0.7 |
| Brief Inventory of Psychosocial Functions (B-IPF) Score(score on a scale) | Brexpiprazole (2 mg) + Sertraline | Brexpiprazole (3 mg) + Sertraline | Sertraline + Placebo | Total |
|---|---|---|---|---|
| Mean | 63.3 ± 20.1 | 62.5 ± 22.4 | 59.9 ± 20.5 | 61.9 ± 21.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Oct 2019 to primary completion in Jul 2023, 44 months.
Results were first posted in May 2025, 1 year 10 months after primary completion. A results delay was requested in Jul 2024.
Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 44 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brexpiprazole · Sertraline
Stress Disorders, Post-Traumatic →
Otsuka Pharmaceutical Development & Commercialization, Inc. →